Clinical trials: Impairment
Parkinson Disease, Freezing of Gait
Use of CereGate Therapy for Freezing of Gait in PD
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
- Conditions
- Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
- Trial name
- NCT05292794
- Testing
- CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- CereGate Inc.
Hepatic Insufficiency
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m2 can take part.
- Trial name
- NCT06957756
- Testing
- BI 1584862
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Subjective Cognitive Decline, Alzheimer Disease
Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns
AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.
- Conditions
- Subjective Cognitive Decline, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- AHEAD (NCT07652931)
- Testing
- High-frequency Transcranial Magnetic Stimulation (TMS), Digital Cognitive Training, Structured Physical Exercise
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS San Raffaele
Neurological Diseases or Conditions, Dementia of Alzheimer Type
An Observational Study of Patients Living With Chronic Neurological Diseases
TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment…
- Conditions
- Neurological Diseases or Conditions, Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT05796037
- Volunteers
- 1,500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alzheimer's Disease
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00454870
- Testing
- MEM 3454
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memory Pharmaceuticals
Parkinson's Disease (PD), Spinal Cord Stimulation (SCS)
Trial of Four Spinal Cord Stimulation Paradigms for Gait Impairment in Parkinson's Disease
Patients with PD and SCS treatment for gait impairment entered a cross-over trial of four stimulation paradigms; high frequency/low pulse width, low frequency/high pulse width, Fast-Acting Sub-perception Therapy, and MicroBurst.
- Trial name
- NCT07659405
- Testing
- Stimulation paradigm: High frequency / low pulse width, Stimulation paradigm: Low frequency / high pulse width, MicroBurst
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- University of Aarhus
Impaired Glucose Tolerance, Insulin Sensitivity
Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose
This study will test the effect of four common oral anti-diabetic agents on hepatic insulin sensitivity in South Asian women with impaired glucose tolerance or impaired fasting glucose.
- Conditions
- Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders
- Trial name
- DIASA3 (NCT04662866)
- Testing
- Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
- Where
- Norway
- Volunteers
- 64 people
- Sponsor
- Oslo University Hospital
Pain, Terminal Illness
Neurotoxic Adverse Effects of Morphine and Oxycodone for Pain in Terminal Patients With Diminished Renal Function
Significant pain is a common condition in dying patients. Continuous subcutaneous infusion (CSCI) of opioids is the cornerstone in treatment of pain in this last phase of life.
- Conditions
- Pain, Terminal Illness, Renal Impairment
- Trial name
- MOSART (NCT03616639)
- Testing
- Oxycodone, Morphine
- Where
- 15 sites in Netherlands
- Volunteers
- 8 people
- Sponsor
- Maastricht University Medical Center
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
- Trial name
- NCT06704542
- Where
- 6 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Parkinson Disease, Cognitive Impairment
Physical Therapy and Cognitive Decline
Background: Mild Cognitive Impairment in Parkinson's disease (PD-MCI) is considered a predictor for the development of dementia, a major source of eventual treatment-refractory disability.
- Trial name
- PD-MCI (NCT04012086)
- Testing
- Physical therapy
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Migraine Disorders, Aphasia
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Stroke-like migraine attacks after radiation therapy-also known as SMART syndrome-constitute a rare condition typically characterized by headache, seizures, vision abnormalities, hemiparesis, and aphasia.
- Trial name
- NCT03662295
- Testing
- Language treatment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Quality Living, Inc.
Moyamoya Disease
Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the…
- Trial name
- NCT06832839
- Testing
- Revascularization
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD4 (NCT03242018)
- Testing
- Sotagliflozin
- Where
- 106 sites in United States, Argentina and 13 more
- Volunteers
- 277 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
Dapagliflozin Treatment in Type 2 Diabetes
Open label, mechanistic, single-arm study to evaluate the natriuretic effect of 2 weeks dapagliflozin treatment in T2DM patients with impaired renal function.
- Trial name
- NCT04620590
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- 2 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Emerald Clinical Inc.
Post COVID-19 Cognitive Impairment
A Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment
Some people who have been infected with the virus that causes COVID-19 can experience long-term effects from their infection, known as post COVID-19 conditions (PCC) or long COVID1.
- Trial name
- NCT05857124
- Testing
- Vielight Neuro RX Gamma active device
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Vielight Inc.
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Crownlands Observing Progression With Neurons Study
The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
- Trial name
- CROWN-I (NCT07611396)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Crownlands
Renal Impairment
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
This is a multi-center, non-randomized, open-label, two-part study to investigate the effect of renal function and hemodialysis on PK of RO7079901.
- Trial name
- NCT02975388
- Testing
- RO7079901
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Concussion, Mild
Impact of Instability Training on Vestibular Dysfunction in Postconcussion Combat Athletes
We are conducting RCT study on concussion on combat sports athlete and there is high incidence of on concussion in this sports and we will find the association between concussion and vestibular impairment and then we will apply…
- Trial name
- NCT07729761
- Testing
- Traditional Physical therapy, Instability training
- Where
- Pakistan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Chronic Rhinosinusitis, Sleep Disorders
Sleep Disturbance and Daytime Fatigue as Predictors of Cognitive Decline and Functional Decline in Chronic Rhinosinusitis
FOCUS-CRS is a cross-sectional observational study examining the relationship between sleep disturbance, daytime fatigue, and cognitive and functional health in patients with chronic rhinosinusitis (CRS).
- Conditions
- Chronic Rhinosinusitis, Sleep Disorders, Fatigue, Cognitive Dysfunction
- Trial name
- SNOOZE-CRS (NCT07242040)
- Testing
- Self-Reported Questionnaires for Sleep, Fatigue, and Quality of Life
- Where
- Egypt
- Volunteers
- 134 people
- Sponsor
- Sinai University
Alzheimer Disease, Mild Cognitive Impairment
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau
Novel blood-based biomarkers of Alzheimer's disease (AD), such as plasma levels of tau phosphorylated at threonine 181 (p-tau181), have shown great promise in detecting early AD pathology.
- Trial name
- NCT05377060
- Testing
- Plasma p-tau risk disclosure, Standard risk disclosure
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.